恩威医药公告，预计2025年度净利润为5650万元至6650万元，同比增长50.68%～77.35%。报告期内， 预计非经常性损益对净利润的影响金额约为750万元。2025年业绩上升的主要原因是主营业务收入增长 带来净利润增加及股权激励计划成本摊销减少所致。 ...

证券代码：301331 证券简称：恩威医药 公告编号：2026-001 恩威医药股份有限公司 2025 年度业绩预告 1、2025 年业绩上升的主要原因是主营业务收入增长带来净利润增加及股权激励计划成本摊销减少 所致。 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向上升 50%以上情形 （1）以区间数进行业绩预告的 项 目 本报告期 上年同期 归属于上市公司股 东的净利润 5,650 ～ 6,650 比上年同期 3,749.75 增长 50.68% ～ 77.35% 扣除非经常性损益 后的净利润 4,900 ～ 5,900 比上年同期 3,472.96 增长 41.09% ～ 69.88% 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所审计。公司已就本次业 绩预告有关事项与会计师事务所进行了预沟通，公司与会计师事务所在本期业绩预告方面不存在重大分 歧。 三、 ...

Market Overview - The Traditional Chinese Medicine (TCM) sector saw a slight increase of 0.31% on January 8, with WoHua Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] Top Performers - WoHua Pharmaceutical (002107) closed at 7.13, up 5.63% with a trading volume of 298,400 shares and a turnover of 210 million yuan [1] - Enwei Pharmaceutical (301331) closed at 29.06, up 5.52% with a trading volume of 29,600 shares and a turnover of 85 million yuan [1] - Jinhua Co., Ltd. (600080) closed at 8.03, up 4.69% with a trading volume of 137,600 shares and a turnover of 110 million yuan [1] Underperformers - Jilin Aodong (000623) closed at 20.04, down 2.48% with a trading volume of 206,000 shares and a turnover of 416 million yuan [2] - Panlong Pharmaceutical (002864) closed at 34.32, down 1.58% with a trading volume of 149,000 shares and a turnover of 524 million yuan [2] - RY Pharmaceutical (600332) closed at 25.04, down 1.57% with a trading volume of 486,000 shares and a turnover of 122 million yuan [2] Capital Flow - The TCM sector experienced a net outflow of 493 million yuan from institutional investors, while retail investors saw a net inflow of 378 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Individual Stock Capital Flow - Huaren Sanjiu (6660000) had a net inflow of 57.91 million yuan from institutional investors, while it faced a net outflow of 51.38 million yuan from speculative funds [3] - Yunnan Baiyao (000538) saw a net inflow of 42.56 million yuan from institutional investors, but also experienced outflows from both speculative and retail investors [3] - Wanbangde (002082) had a net inflow of 26.36 million yuan from institutional investors, with outflows from speculative and retail investors [3]

Group 1 - Enwei Pharmaceutical's stock price increased by 5.16% on January 8, reaching 28.96 CNY per share, with a total market capitalization of 2.98 billion CNY [1] - The company has experienced a continuous rise in stock price for four consecutive days, with a cumulative increase of 5.8% during this period [1] - Enwei Pharmaceutical specializes in the research, production, and sales of traditional Chinese medicine and chemical drugs, focusing on gynecological products, pediatric medications, and respiratory system drugs [1] Group 2 - According to data, a fund managed by China Merchants Asset Management holds a significant position in Enwei Pharmaceutical, with 7,900 shares, accounting for 1.14% of the fund's net value [2] - The fund, China Merchants Asset Management Zhida Quantitative Stock Mixed Fund A, has generated a floating profit of approximately 11,200 CNY today and 11,900 CNY during the four-day rising period [2] - The fund has a total asset size of 20.91 million CNY and has achieved a year-to-date return of 3.7% [2]

Core Viewpoint - A total of 13 A-shares are undergoing equity registration today, with significant dividend distributions announced by several companies [1] Group 1: Dividend Distribution - Huari Precision, Enwei Pharmaceutical, and Mould Technology are offering the highest dividends, with payouts of 6.00 yuan, 3.50 yuan, and 3.27 yuan per 10 shares respectively [1] - Five additional companies have proposed dividend distributions, with Dongmu Co., Fuan Energy, and Anfu Technology planning to distribute 3.0 yuan, 2.5 yuan, and 1.2 yuan per 10 shares respectively [1]

Group 1 - The core viewpoint of the news is that Enwei Pharmaceutical has shown a mixed performance in terms of financing and stockholder metrics, with a notable increase in revenue and net profit year-on-year [1][2][3] Group 2 - As of December 31, Enwei Pharmaceutical's stock price increased by 0.23%, with a trading volume of 18.41 million yuan. The financing buy-in amount was 1.50 million yuan, while the financing repayment was 1.84 million yuan, resulting in a net financing buy of -0.34 million yuan [1] - The total balance of margin trading for Enwei Pharmaceutical reached 76.83 million yuan, accounting for 2.82% of its market capitalization, which is above the 50th percentile level over the past year [1] - The company specializes in the research, production, and sales of traditional Chinese medicine and chemical drugs, focusing on gynecological products, pediatric medications, and respiratory system drugs [1] - For the period from January to September 2025, Enwei Pharmaceutical achieved an operating income of 637 million yuan, representing a year-on-year growth of 13.65%, and a net profit attributable to shareholders of 36.58 million yuan, which is a 66.13% increase year-on-year [2] - The number of shareholders as of September 30 was 6,340, a decrease of 13.72% from the previous period, while the average circulating shares per person increased by 261.71% [2] - Enwei Pharmaceutical has distributed a total of 221 million yuan in dividends since its A-share listing [3]

Core Viewpoint - Enwei Pharmaceutical Co., Ltd. has announced its 2025 interim dividend distribution plan, which includes a cash dividend of RMB 3.50 per 10 shares for shareholders, based on a total share capital of 101,836,561 shares after excluding repurchased shares [2][4]. Group 1: Dividend Distribution Plan - The company will distribute a cash dividend of RMB 3.50 per 10 shares (including tax), amounting to a total cash dividend of RMB 35,642,796.35 [2][4]. - The dividend distribution is based on the total share capital of 102,891,887 shares, minus the repurchased shares of 1,055,326, resulting in a distribution base of 101,836,561 shares [2][4]. - The cash dividend per share, calculated based on the total share capital, is approximately RMB 0.3464101 [14]. Group 2: Shareholder Meeting and Approval - On May 12, 2025, the company's annual shareholder meeting approved the proposal to authorize the board to formulate and implement the 2025 interim profit distribution plan [3]. - The board of directors approved the interim dividend plan on December 26, 2025, confirming the distribution method and amount [4][5]. Group 3: Key Dates - The record date for the dividend distribution is set for January 7, 2026, and the ex-dividend date is January 8, 2026 [8][9]. Group 4: Dividend Payment Method - The cash dividends will be directly credited to the shareholders' accounts through the securities custody company on the ex-dividend date [11]. - The company will bear all legal responsibilities if there are any discrepancies in the dividend distribution due to changes in shareholders' accounts during the application period [12].

Group 1 - The company Enwei Pharmaceutical announced a cash dividend plan for the first half of 2025, distributing RMB 3.50 per 10 shares to shareholders, totaling RMB 35,642,796.35 [1] - The dividend will be based on a total share count of 101,836,561 shares after excluding repurchased shares [1] - The record date for the dividend is set for January 7, 2026, with the ex-dividend date on January 8, 2026 [1] Group 2 - A new type of chip has been developed in China, which can support AI training and embodied intelligence, and can be mass-produced using mature processes of 28 nanometers and above [1] - This development aims to circumvent the challenges posed by the restrictions on lithography machines [1]

证券代码：301331 证券简称：恩威医药 公告编号：2025-059 恩威医药股份有限公司 2025 年中期分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、恩威医药股份有限公司（以下简称"公司"）回购专用证券账户中的股 份 1,055,326 股不参与本次分红派息。公司 2025 年中期分红派息方案为：以公司 现有总股本 102,891,887 股剔除已回购股份 1,055,326 股后的 101,836,561 股为基 数：向全体股东每 10 股派发现金红利人民币 3.50 元（含税），实际派发现金红 利总额 35,642,796.35 元（具体以中国证券登记结算有限公司深圳分公司实际登 记结果为准），不送红股，不以资本公积金转增股本； 2、本次分红派息实施后计算除权除息价格时，按公司总股本（含回购股份） 折算的每股现金红利（含税）=现金红利总额÷总股本=35,642,796.35 元÷ 102,891,887 股=0.3464101 元/股。本次分红派息实施后除权除息参考价=（除权 除息日前一交易日收盘价-按公司总股本折 ...

证券日报网讯 12月26日，恩威医药发布公告称，公司2025年中期分红方案为：拟每10股派3.50元（含 税），预计派现总额约3564万元，股权登记日将另行公告，无需再提交股东会审议。 （文章来源：证券日报） ...